ArticleHuman vaccines & immunotherapeutics2023
Assessing SARS-CoV-2 vaccine hesitancy among the people living with and without HIV from May to September 2022 in Blantyre, Malawi.
Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 3 syntheses or guidelines pooled it, 6 citations in OpenAlex.
- Vaccine hesitancy in context of COVID-19 in East Africa: systematic review and meta-analysis.BMC public health · 2024Pooled it
- A Systematic Review of Factors Associated with COVID-19 Vaccine Uptake, Hesitancy, and Acceptability Among Adults with HIV: Implications for Integrating COVID-19 Immunization into HIV Care.AIDS patient care and STDs · 2024Pooled it
- A systematic review and meta-analysis of the global prevalence and determinants of COVID-19 vaccine acceptance and uptake in people living with HIV.Nature human behaviour · 2024Pooled it
- COVID-19 vaccination hesitancy among Malawians: a scoping review.Systematic reviews · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccine hesitancy is a significant obstacle to the prevention and control of coronavirus disease 2019, especially among people with human immunodeficiency virus (HIV) in developing countries like Malawi, where HIV prevalence rate is high and limited data is available on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine hesitancy among people living with HIV (PLHIV). This study was conducted among people aged ≥18 years at Mpemba health center, Blantyre. All PLHIV were interviewed using a structured questionnaire. All non-PLHIVs who were willing and were conveniently available were investigated. Multivariate logistic regression model and generalized linear model were used to assess the factors associated with SARS-CoV-2 vaccine hesitancy and knowledge, attitude, and trust. Totally 682 subjects were recruited with 341 PLHIV and 341 non-PLHIV. SARS-CoV-2 vaccine hesitancy rates were similar between PLHIV and non-PLHIV (56.0% vs. 57.2%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.